ReviewJournal of molecular neuroscience : MN2025
Cannabinoids and ADHD: a New Frontier in Neuropharmacology?
Review in Journal of molecular neuroscience : MN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Attention deficit hyperactivity disorder (ADHD) is a disorder characterized by symptoms of inattention, impulsivity, and hyperactivity, which can significantly impair individuals' quality of life and lead to various challenges in their social interactions, relationships, professional endeavors, and academic pursuits. This disorder can manifest in both children and adults, and it has been established that genetic and environmental factors contribute to its etiology. Existing data indicate that individuals with ADHD are at a higher risk of substance use, and some may develop cannabis dependence or engage in self-medication with it. It has been hypothesized that individuals with ADHD may utilize cannabis to mitigate certain symptoms, such as anxiety, or to alleviate the adverse effects of their prescribed medication. Furthermore, both in vivo and clinical investigations have reported that cannabinoids, including cannabidiol, may possess potential therapeutic effects in ADHD patients or animal models. This study aims to provide a comprehensive review of the current literature on the impact of cannabinoids on ADHD and to elucidate the possible pharmacological mechanisms through which cannabinoids might exert their therapeutic outcomes.
Indexed as
Identifiers
41165995What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.